3TC's clear improvement over AZT

3TC's clear improvement over AZT

Researchers on Sunday were to present positive results from two European Phase II/III studies of BioChem Pharma Inc.'s 3TC nucleoside analog in AIDS patients, which BCHXF said will allow partner Glaxo to file for worldwide marketing approval in the first half of 1995.

A total of 352 patients were tested in both trials, which produced statistically significant results on three measures: increased CD4 counts, virus levels in blood and in blood plasma serum.

The smaller of the two trials was a 129-patient double-blind trial comparing 24 weeks of treatment with 200

Read the full 945 word article

How to gain access

Continue reading with a
two-week free trial.